Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6639835,elimination half-lives,"The elimination half-lives were 10.9, 10.4, and 4.1 h, for AC, AM and AA, respectively.",Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639835/),h,10.9,10113,DB01418,Acenocoumarol
,6639835,elimination half-lives,"The elimination half-lives were 10.9, 10.4, and 4.1 h, for AC, AM and AA, respectively.",Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639835/),h,10.4,10114,DB01418,Acenocoumarol
,6639835,elimination half-lives,"The elimination half-lives were 10.9, 10.4, and 4.1 h, for AC, AM and AA, respectively.",Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639835/),h,4.1,10115,DB01418,Acenocoumarol
,6639835,maximum effect,The oral administration of AC resulted in a rise in prothrombin time with a maximum effect at 24 to 30 h.,Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639835/),h,24 to 30,10116,DB01418,Acenocoumarol
,8220911,Kis,6. Sulphaphenazole competitively inhibits the 7- and in some samples partly (up to 50%) the 6-hydroxylation of S-warfarin as well as the 7-hydroxylation of R- and S-acenocoumarol and the 6-hydroxylation of S-acenocoumarol (Kis ranging from 0.5-1.3 microM).,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,0.5-1.3,27727,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,99,27728,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,117,27729,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,219,27730,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.2,27731,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,6.1,27732,DB01418,Acenocoumarol
,8220911,Ki,7. Omeprazole partly (40-80%) inhibits the 6- and 7-hydroxylation of R-warfarin (Ki = 99 and 117 microM) and of R- (Ki = 219 and 7.2 microM) and S-acenocoumarol (Ki = 6.1 and 7.7 microM) but not S-warfarin in a competitive manner.,Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8220911/),μM,7.7,27733,DB01418,Acenocoumarol
,14739663,area under the concentration-time curve up to 24 h,Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2.56 and 1.58 h*micromol/L) compared to the systemic exposure in the absence of E7070 (1.87 and 1.23 h*micromol/l).,Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14739663/),[h·μM] / [l],2.56,33153,DB01418,Acenocoumarol
,14739663,area under the concentration-time curve up to 24 h,Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2.56 and 1.58 h*micromol/L) compared to the systemic exposure in the absence of E7070 (1.87 and 1.23 h*micromol/l).,Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14739663/),[h·μM] / [l],1.58,33154,DB01418,Acenocoumarol
,14739663,area under the concentration-time curve up to 24 h,Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2.56 and 1.58 h*micromol/L) compared to the systemic exposure in the absence of E7070 (1.87 and 1.23 h*micromol/l).,Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14739663/),[h·μM] / [l],1.87,33155,DB01418,Acenocoumarol
,14739663,area under the concentration-time curve up to 24 h,Pharmacokinetic parameters of acenocoumarol were calculated by noncompartmental analysis and revealed that in both patients the area under the concentration-time curve up to 24 h after the acenocoumarol administration was higher following E7070 (2.56 and 1.58 h*micromol/L) compared to the systemic exposure in the absence of E7070 (1.87 and 1.23 h*micromol/l).,Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14739663/),[h·μM] / [l],1.23,33156,DB01418,Acenocoumarol
,14739663,plasma protein binding,The plasma protein binding of acenocoumarol was reduced at higher concentrations of E7070 (259 microM).,Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14739663/),μM,259,33157,DB01418,Acenocoumarol
≥,23651023,International Normalized Ratio,Overanticoagulation was defined as the occurrence of at least one International Normalized Ratio ≥4.,Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23651023/),,4,49609,DB01418,Acenocoumarol
,15986763,plasma,The highest plasma average concentration of acenocoumarin was found in day 45th postpartum (0.21 microg/mL).,[Plasma and milk concentrations of acenocoumarin in breast-feeding women during post partum]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15986763/),[μg] / [ml],0.21,52680,DB01418,Acenocoumarol
,15986763,excretion index,"The value of the maternal milk excretion index was 0.057 in day 45, what represents that approximately the 5% of acenocoumarin is eliminated by milk.",[Plasma and milk concentrations of acenocoumarin in breast-feeding women during post partum]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15986763/),,0.057,52681,DB01418,Acenocoumarol
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],8.0,61432,DB01418,Acenocoumarol
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],4.3,61433,DB01418,Acenocoumarol
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],4.9,61434,DB01418,Acenocoumarol
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],3.4,61435,DB01418,Acenocoumarol
,2870155,clearances,"Hypothermia further reduced the clearances of the compounds to 0.9 +/- 0.1 and 2.5 +/- 0.2 ml min-1 for ICG and AC, respectively.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],0.9,61436,DB01418,Acenocoumarol
,2870155,clearances,"Hypothermia further reduced the clearances of the compounds to 0.9 +/- 0.1 and 2.5 +/- 0.2 ml min-1 for ICG and AC, respectively.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],2.5,61437,DB01418,Acenocoumarol
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB01418,Acenocoumarol
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB01418,Acenocoumarol
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB01418,Acenocoumarol
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB01418,Acenocoumarol
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB01418,Acenocoumarol
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB01418,Acenocoumarol
,7487286,half life,Its half life is about three hours when administered intravenously which requires continuous infusion whereas subcutaneous administration can ensure stable plasma concentrations and antithrombotic activity over a period of approximatively 12 hours.,[Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis. A pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7487286/),h,three,84617,DB01418,Acenocoumarol
,2906600,plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],2.8,92466,DB01418,Acenocoumarol
,2906600,plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],1.54,92467,DB01418,Acenocoumarol
,2906600,unbound plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],67,92468,DB01418,Acenocoumarol
,2906600,unbound plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],140,92469,DB01418,Acenocoumarol
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],62,92470,DB01418,Acenocoumarol
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],22,92471,DB01418,Acenocoumarol
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],337,92472,DB01418,Acenocoumarol
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],141,92473,DB01418,Acenocoumarol
,2906600,rate constant,This effect is probably due to stimulation of a hepatic biliary transport system; the rate constant for transport of 7-hydroxy-acenocoumarol was enhanced 5-fold (0.107 +/- 0.03 vs. 0.021 +/- 0.007 min-1).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),1/[min],0.107,92474,DB01418,Acenocoumarol
,2906600,rate constant,This effect is probably due to stimulation of a hepatic biliary transport system; the rate constant for transport of 7-hydroxy-acenocoumarol was enhanced 5-fold (0.107 +/- 0.03 vs. 0.021 +/- 0.007 min-1).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),1/[min],0.021,92475,DB01418,Acenocoumarol
,8001599,peak plasma concentration,The peak plasma concentration of 244.19-644.23 micrograms/l was reached 1-4 h after drug administration.,Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001599/),[μg] / [l],244.19-644.23,100468,DB01418,Acenocoumarol
,8001599,terminal phase half-life,The terminal phase half-life was 6.29-14.22 h and a systemic clearance was 1.86-5.62 l/h.,Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001599/),h,6.29-14.22,100469,DB01418,Acenocoumarol
,8001599,systemic clearance,The terminal phase half-life was 6.29-14.22 h and a systemic clearance was 1.86-5.62 l/h.,Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001599/),[l] / [h],1.86-5.62,100470,DB01418,Acenocoumarol
,8001599,systemic availability,The systemic availability was 94.22-98.01% and the elimination of the drug on its first-pass through the liver was 1.99-5.78%.,Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001599/),%,94.22-98.01,100471,DB01418,Acenocoumarol
,8001599,elimination,The systemic availability was 94.22-98.01% and the elimination of the drug on its first-pass through the liver was 1.99-5.78%.,Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001599/),%,1.99-5.78,100472,DB01418,Acenocoumarol
,6141241,half-life of decline,A rapid onset of the hypothrombogenic effect was observed for all three derivatives with the half-life of decline of PCA = 3.6 h.,Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),h,3.6,148794,DB01418,Acenocoumarol
,6141241,half-life of elimination,"The duration of the hypothrombogenic effect was short for the drug and its AA derivative and long for the AM compound (normalization at about 24 and 70 h, respectively), parallelling the half-life of elimination of the compounds of, 3.3, 4, and 8 h respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),h,3.3,148795,DB01418,Acenocoumarol
,6141241,half-life of elimination,"The duration of the hypothrombogenic effect was short for the drug and its AA derivative and long for the AM compound (normalization at about 24 and 70 h, respectively), parallelling the half-life of elimination of the compounds of, 3.3, 4, and 8 h respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),h,4,148796,DB01418,Acenocoumarol
,6141241,half-life of elimination,"The duration of the hypothrombogenic effect was short for the drug and its AA derivative and long for the AM compound (normalization at about 24 and 70 h, respectively), parallelling the half-life of elimination of the compounds of, 3.3, 4, and 8 h respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),h,8,148797,DB01418,Acenocoumarol
higher,6141241,liver to plasma ratio,The liver to plasma ratio was higher than 1 beyond 10 min after administration.,Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),,1,148798,DB01418,Acenocoumarol
,6141241,Plasma protein binding,"Plasma protein binding was extensive, being the highest for the drug; 1.81, 2.84 and 3.89% free for drug, AM, and AA derivative, respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),%,1.81,148799,DB01418,Acenocoumarol
,6141241,Plasma protein binding,"Plasma protein binding was extensive, being the highest for the drug; 1.81, 2.84 and 3.89% free for drug, AM, and AA derivative, respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),%,2.84,148800,DB01418,Acenocoumarol
,6141241,Plasma protein binding,"Plasma protein binding was extensive, being the highest for the drug; 1.81, 2.84 and 3.89% free for drug, AM, and AA derivative, respectively.",Acenocoumarol and its amino and acetamido metabolites. Comparative pharmacokinetics and pharmacodynamics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141241/),%,3.89,148801,DB01418,Acenocoumarol
,12844136,oral clearance,"The mean oral clearance of S-acenocoumarol was 45% lower in the CYP2C9*1/*3 genotypes (10.9 +/- 3.0 L/h versus 19.8 +/- 3.1 L/h, P =.02).",Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844136/),[l] / [h],10.9,178921,DB01418,Acenocoumarol
,12844136,oral clearance,"The mean oral clearance of S-acenocoumarol was 45% lower in the CYP2C9*1/*3 genotypes (10.9 +/- 3.0 L/h versus 19.8 +/- 3.1 L/h, P =.02).",Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844136/),[l] / [h],19.8,178922,DB01418,Acenocoumarol
,12844136,Plasma half-life,Plasma half-life was prolonged from 1.0 +/- 0.2 hours to 2.0 +/- 0.7 hours (P =.09).,Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844136/),h,1.0,178923,DB01418,Acenocoumarol
,12844136,Plasma half-life,Plasma half-life was prolonged from 1.0 +/- 0.2 hours to 2.0 +/- 0.7 hours (P =.09).,Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844136/),h,2.0,178924,DB01418,Acenocoumarol
,12844136,international normalized ratio,"There was no difference in mean international normalized ratio at 24 hours, which was 1.2 in both groups.",Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12844136/),,1.2,178925,DB01418,Acenocoumarol
,3408639,clearance/bioavailability,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),[1] / [h],1.28,186671,DB01418,Acenocoumarol
,3408639,clearance/bioavailability,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),[1] / [h],17.5,186672,DB01418,Acenocoumarol
,3408639,volume of distribution/bioavailability,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),1,12.5,186673,DB01418,Acenocoumarol
,3408639,volume of distribution/bioavailability,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),1,22.6,186674,DB01418,Acenocoumarol
,3408639,terminal half-life,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),h,6.8,186675,DB01418,Acenocoumarol
,3408639,terminal half-life,"3. The mean pharmacokinetic parameters of the individual enantiomers were: clearance/bioavailability 1.28 1 h-1, R-enantiomer; 17.5 1 h-1, S-enantiomer: volume of distribution/bioavailability 12.5 1, R-enantiomer; 22.6 1, S-enantiomer: terminal half-life 6.8 h, R-enantiomer; 0.91 h, S-enantiomer.",Stereospecific assay of nicoumalone: application to pharmacokinetic studies in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3408639/),h,0.91,186676,DB01418,Acenocoumarol
,3694526,distribution,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,0.25,201486,DB01418,Acenocoumarol
,3694526,beta-phase (T1/2,"When administered in microdoses (9 micrograms i.v.) to rats (male Wistars, 270-300 g), a steep distribution phase (T1/2 = 0.25 hr) was followed by a relatively slow beta-phase (T1/2 = 40 hr).","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,40,201487,DB01418,Acenocoumarol
,3694526,volume of distribution,The observed volume of distribution was 390 ml.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,390,201488,DB01418,Acenocoumarol
,3694526,volume of distribution,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),ml,45,201489,DB01418,Acenocoumarol
,3694526,T1/2,"This pharmacokinetic behavior contrasted highly with the one seen for higher (greater than 0.2 mg/kg) doses (unlabeled) warfarin; volume of distribution = 45 ml, T1/2 = 12.5 hr.","Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),h,12.5,201490,DB01418,Acenocoumarol
,3694526,rate of appearance,The rate of appearance of [14C]warfarin was 0.3 hr-1 irrespective the 4-hydroxycoumarin used.,"Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694526/),1/[h],0.3,201491,DB01418,Acenocoumarol
,9483171,plasma half-life,The plasma half-life of phenprocoumon was approximately 350 h (normal 120-150 h).,Vitamin K metabolism in a patient resistant to vitamin K antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9483171/),h,350,209422,DB01418,Acenocoumarol
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,1.2,214118,DB01418,Acenocoumarol
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,5.5,214119,DB01418,Acenocoumarol
,14741071,area under the concentration-time curve (AUC(0-t)),"The mean (coefficient of variation (CV%)) area under the concentration-time curve (AUC(0-t)) of R-acenocoumarol in the presence and absence of nateglinide was 4217 (23%) and 3831 (24%) ng.h/ml, respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),[h·ng] / [ml],4217,214948,DB01418,Acenocoumarol
,14741071,area under the concentration-time curve (AUC(0-t)),"The mean (coefficient of variation (CV%)) area under the concentration-time curve (AUC(0-t)) of R-acenocoumarol in the presence and absence of nateglinide was 4217 (23%) and 3831 (24%) ng.h/ml, respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),[h·ng] / [ml],3831,214949,DB01418,Acenocoumarol
,14741071,AUC,"The corresponding AUC(INR) values were 104 (13%) and 99 (10%), respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),,104,214950,DB01418,Acenocoumarol
,14741071,AUC,"The corresponding AUC(INR) values were 104 (13%) and 99 (10%), respectively.",The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14741071/),,99,214951,DB01418,Acenocoumarol
,22773430,AUC0-24,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[h·ng] / [ml],1 364.38,217703,DB01418,Acenocoumarol
,22773430,AUC0-24,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[h·ng] / [ml],1 328.39,217704,DB01418,Acenocoumarol
,22773430,AUC0-∞,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[h·ng] / [ml],1 786.00,217705,DB01418,Acenocoumarol
,22773430,AUC0-∞,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[h·ng] / [ml],1 706.71,217706,DB01418,Acenocoumarol
,22773430,Cmax,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[ng] / [ml],180.69,217707,DB01418,Acenocoumarol
,22773430,Tmax,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),h,1.83,217708,DB01418,Acenocoumarol
,22773430,Tmax,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),[ng] / [ml],186.97,217709,DB01418,Acenocoumarol
,22773430,Tmax,The values of the pharmacokinetic parameters were (mean ± SD): AUC0-24 =1 364.38±499.26 ngxh/mL for the test and 1 328.39±429.20 ngxh/mL for the reference; AUC0-∞ =1 786.00±732.85 ngxh/mL for the test and 1 706.71±599.66 ngxh/mL for the reference; Cmax =180.69±35.11 ng/mL with a Tmax of 1.83±0.95 h for the test and 186.97±38.21 ng/mL with a Tmax of 2.19±0.83 h for the reference.,"Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),h,2.19,217710,DB01418,Acenocoumarol
,22773430,t1/2,"Regarding half life measurements, the mean ± SD of t1/2 were 11.84±4.54 h for the test and 11.08±3.28 h for the reference.","Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),h,11.84,217711,DB01418,Acenocoumarol
,22773430,t1/2,"Regarding half life measurements, the mean ± SD of t1/2 were 11.84±4.54 h for the test and 11.08±3.28 h for the reference.","Bioequivalence of acenocoumarol in chilean volunteers: an open, randomized, double-blind, single-dose, 2-period, and 2-sequence crossover study for 2 oral formulations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22773430/),h,11.08,217712,DB01418,Acenocoumarol
,3758150,mean residence time (MRT),"The mean residence time (MRT) of R-AC was about 10 times longer than that of S-AC, 15 h vs 1.2 h.",Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758150/),h,15,218411,DB01418,Acenocoumarol
,3758150,mean residence time (MRT),"The mean residence time (MRT) of R-AC was about 10 times longer than that of S-AC, 15 h vs 1.2 h.",Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758150/),h,1.2,218412,DB01418,Acenocoumarol
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3458,233825,DB01418,Acenocoumarol
,10027662,areas under the concentration-time curve (AUC),The median (range) areas under the concentration-time curve (AUC) for (R)-acenocoumarol were 3458 (3035-7312) microg x h 1(-1) in the absence of and 3667 (2907-7741) microg x h 1(-1) in the presence of lornoxicam.,No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027662/),h·μg,3667,233826,DB01418,Acenocoumarol
,9684795,clearance,Estimated clearance was 2.4 1/h (20% inter-individual variability and 9% inter-period variability).,Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9684795/),[1] / [h],2.4,234598,DB01418,Acenocoumarol
,9684795,volume of distribution at steady-state,"The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively, with 16% inter-individual variability.",Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9684795/),[ml] / [kg],78,234599,DB01418,Acenocoumarol
,9684795,volume of distribution at steady-state,"The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively, with 16% inter-individual variability.",Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9684795/),[ml] / [kg],88,234600,DB01418,Acenocoumarol
,2865109,total clearance,"The differences in elimination between the AC enantiomers were entirely due to differences in total clearance, 183 +/- 14 and 714 +/- 148 ml X h-1 X kg-1 (+/- SD) for R(+)- and S(-)-AC.",Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865109/),[ml] / [h·kg],183,236582,DB01418,Acenocoumarol
,2865109,total clearance,"The differences in elimination between the AC enantiomers were entirely due to differences in total clearance, 183 +/- 14 and 714 +/- 148 ml X h-1 X kg-1 (+/- SD) for R(+)- and S(-)-AC.",Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865109/),[ml] / [h·kg],714,236583,DB01418,Acenocoumarol
,2865109,body clearance,"Also the differences in elimination between the AM enantiomers were mainly due to differences in body clearance, 50 +/- 13 and 18 +/- 4 ml X h-1 X kg-1 for R(+)- and S(-)-AM.",Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865109/),[ml] / [h·kg],50,236584,DB01418,Acenocoumarol
,2865109,body clearance,"Also the differences in elimination between the AM enantiomers were mainly due to differences in body clearance, 50 +/- 13 and 18 +/- 4 ml X h-1 X kg-1 for R(+)- and S(-)-AM.",Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2865109/),[ml] / [h·kg],18,236585,DB01418,Acenocoumarol
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],3016,274191,DB01418,Acenocoumarol
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],233,274192,DB01418,Acenocoumarol
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],2929,274193,DB01418,Acenocoumarol
,9354316,AUC,"The pharmacokinetics of R- and S-acenocoumarol (AUC 3016 +/- 221 and 233 +/- 14 ng ml(-1) h, respectively) did not change after omeprazole (AUC 2929 +/- 256 and 220 +/- 18 ng ml(-1) h, respectively).",No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9354316/),[h·ng] / [ml],220,274194,DB01418,Acenocoumarol
